{"id":16766,"date":"2022-03-28T17:47:08","date_gmt":"2022-03-28T12:17:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=16766"},"modified":"2022-12-16T11:53:13","modified_gmt":"2022-12-16T06:23:13","slug":"fabry-disease-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape","title":{"rendered":"Examining the Therapeutic Advances in Fabry Disease Treatment Landscape"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0b5ea5730f3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0b5ea5730f3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Fabry_Disease_Epidemiology_and_Statistics\" >Fabry Disease Epidemiology and Statistics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Fabry_Disease_Market_Insights\" >Fabry Disease Market Insights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Current_Fabry_Disease_Treatment_Landscape\" >Current Fabry Disease Treatment Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Emerging_Drugs_in_Fabry_Disease_Treatment_Pipeline\" >Emerging Drugs in Fabry Disease Treatment Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Unmet_Needs_in_Fabry_Disease_Treatment_Domain\" >Unmet Needs in Fabry Disease Treatment Domain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Way_Ahead\" >Way Ahead<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\/#Frequently_Asked_Questions_FAQs\" >Frequently Asked Questions (FAQs)<\/a><\/li><\/ul><\/nav><\/div>\n\n<p id=\"h-fabry-disease-is-an-inherited-lysosomal-storage-disease-caused-by-a-nonfunctional-or-partially-functional-enzyme-called-alpha-galactosidase-a-\u03b1-gal-a-decreased-activity-of-\u03b1-gal-a-in-lysosomes-results-in-the-accumulation-of-enzyme-substrates-gb3-and-lyso-gb3-which-cause-cellular-damage-in-tissues-throughout-the-body-currently-there-is-no-permanent-cure-for-fabry-disease-but-recent-developments-in-the-fabry-disease-treatment-scenario-are-leading-to-a-symptomatic-cure-relieving-the-condition-fabry-disease-symptoms-include-pain-that-spreads-through-the-body-called-a-fabry-crisis-gastrointestinal-complications-headaches-impaired-sweating-vertigo-and-hearing-impairment\">Fabry Disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme called alpha galactosidase A (\u03b1-Gal A). Decreased activity of \u03b1-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout the body. Currently, there is no permanent cure for Fabry Disease. But, recent developments in the Fabry Disease treatment scenario are leading to a symptomatic cure, relieving the condition. Fabry Disease symptoms include pain that spreads through the body (called a Fabry crisis), <a href=\"https:\/\/www.delveinsight.com\/blog\/digestive-disorders\">gastrointestinal complications<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/cluster-headache-market\">headaches<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/vasomotor-symptoms-market\">impaired sweating<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/vertigo-market\">vertigo<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/blog\/hearing-loss-treatment-market\">hearing impairment<\/a>.<\/p>\n\n\n\n<p>It was once thought that Fabry Disease inheritance only affected males and females were considered to be the \u201ccarriers.\u201d However, it is now known that both men and women can get Fabry Disease, though it may manifest differently depending on gender. Despite being X-linked, heterozygous women may experience all the Fabry Disease signs and symptoms that are also seen in men. But when compared with hemizygous males, Fabry Disease symptoms in females typically emerge at an older age and with less severity.<\/p>\n\n\n\n<p>For Fabry Disease diagnosis, a GLA gene test can be performed. This exclusive Fabry Disease test aims at measuring the level of the alpha-GAL enzyme. If the alpha-GAL enzyme assay shows low enzyme activity, then the person is considered to have experience Fabry disease onset. Males with classic Fabry disease essentially have no alpha-galactosidase A enzyme (less than 1% of normal). Whereas, for females, a DNA test for Fabry Disease diagnosis is the most prescribed. Fabry Disease can be classified into two forms &#8211; <strong>Classic Fabry Disease <\/strong>and <strong>Late onset Fabry Disease.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fabry_Disease_Epidemiology_and_Statistics\"><\/span><strong>Fabry Disease Epidemiology and Statistics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Fabry Disease is an extremely rare and inherited genetic disorder that can lead to life-threatening heart attacks and kidney problems such as kidney failure. This disorder belongs to a group of diseases known as lysosomal storage disorders. It affects one in many, and Fabry Disease incidence is observed in both the genders. As per DelveInsight, <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-epidemiology-forecast\">Fabry Disease prevalence<\/a> in the <strong>7MM countries<\/strong> was estimated to be <strong>13,050 cases<\/strong> in the year 2020. Out of which, the United States was observed to have the highest Fabry Disease prevalence, where males accounted for<strong> <\/strong><strong>4,111 cases<\/strong> and <strong>3,820 females<\/strong> were affected with Fabry Disease. DelveInsight estimates that the number will increase by 2030.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-5cd639ef-d819-4364-b983-b0edf576e1ff\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 481 400\" width=\"481\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.0.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-8rs3yiu-826-\"><rect fill=\"none\" height=\"310\" width=\"385\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-8rs3yiu-831-\"><rect fill=\"none\" height=\"310\" width=\"385\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-8rs3yiu-832-\"><rect fill=\"none\" height=\"310\" width=\"385\" x=\"86\" y=\"53\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"481\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"310\" width=\"385\" x=\"86\" y=\"53\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 181.5 53 L 181.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 278.5 53 L 278.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 374.5 53 L 374.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 470.5 53 L 470.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 85.5 53 L 85.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 86 363.5 L 471 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 86 311.5 L 471 311.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 86 260.5 L 471 260.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 86 208.5 L 471 208.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 86 156.5 L 471 156.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 86 105.5 L 471 105.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 86 52.5 L 471 52.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"310\" width=\"385\" x=\"86\" y=\"53\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 86 363.5 L 471 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.00968360900879 208)\" x=\"26.00968360900879\" y=\"208\">Total Prevalent Population<\/text><path class=\"highcharts-axis-line\" d=\"M 86 53 L 86 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" aria-label=\"\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-8rs3yiu-831-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(86,53) scale(1 1)\"><rect aria-label=\"1. 7MM, 13,050. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"270\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"47\" x=\"24.5\" y=\"40.5\"><\/rect><rect aria-label=\"2. United States, 7,931. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"164\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"47\" x=\"120.5\" y=\"146.5\"><\/rect><rect aria-label=\"3. EU5, 4,682. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"97\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"47\" x=\"217.5\" y=\"213.5\"><\/rect><rect aria-label=\"4. Japan, 437. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"9\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"47\" x=\"313.5\" y=\"301.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(86,53) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"241\" y=\"24\">Fabry Disease Epidemiology<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"241\" y=\"52\"><\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(86,53) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(23,163)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">13 050<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>13 050<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(123,216)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">7 931<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>7 931<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(220,250)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">4 682<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>4 682<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(321,291)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">437<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>437<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"134.125\" y=\"382\">7MM<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"230.375\" y=\"382\">United States<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"326.625\" y=\"382\">EU5<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"422.875\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"315\">2.5k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"264\">5k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"212\">7.5k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"160\">10k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"109\">12.5k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"71\" y=\"57\">15k<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Delveinsight.com\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"471\" y=\"395\">Delveinsight.com<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-8rs3yiu-832-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){Highcharts.setOptions({lang:{}});var options={\"title\":{\"text\":\" Fabry Disease Epidemiology\"},\"subtitle\":{\"text\":\"\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"stacking\":\"normal\",\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Total Prevalent Population\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Geography\\\";\\\"Total Prevalent Population\\\"\\n\\\"7MM\\\";13050\\n\\\"United States\\\";7931\\n\\\"EU5\\\";4682\\n\\\"Japan\\\";437\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Total Prevalent Population\"}}],\"legend\":{\"enabled\":false,\"layout\":\"horizontal\"},\"credits\":{\"href\":\"http:\/\/www.delveinsight.com\",\"text\":\"Delveinsight.com\"},\"pane\":{\"background\":[]},\"responsive\":{\"rules\":[]},\"xAxis\":[{}],\"tooltip\":{},\"lang\":{}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-5cd639ef-d819-4364-b983-b0edf576e1ff\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>In 2020, among the 7MM countries, there were <strong>7,931 prevalent cases of Fabry Disease<\/strong> in the United States. The EU5 countries accounted for <strong>4,682 cases<\/strong>, whereas Japan had a total of <strong>437<\/strong> Fabry Disease cases. Among EU5 countries, the UK had the highest Fabry Disease population which was <strong>1,113 cases, <\/strong>the same year. <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-epidemiology-forecast\">Fabry Disease epidemiology segmentation<\/a> can be done on the basis of prevalent cases of Fabry Disease, Gender-specific cases of Fabry Disease, Phenotype-specific cases of Fabry, and Disease and Age-specific cases of Fabry Disease.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-95650063-6e53-479c-bc58-0632192dafbf\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 492 400\" width=\"492\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.0.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-8o90n3n-466-\"><rect fill=\"none\" height=\"314\" width=\"286\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-8o90n3n-470-\"><rect fill=\"none\" height=\"314\" width=\"286\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-8o90n3n-471-\"><rect fill=\"none\" height=\"286\" width=\"314\" x=\"168\" y=\"53\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"492\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"286\" width=\"314\" x=\"168\" y=\"53\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 168 148.5 L 482 148.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 168 244.5 L 482 244.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 168 339.5 L 482 339.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 168 53.5 L 482 53.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 167.5 53 L 167.5 339\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 230.5 53 L 230.5 339\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 293.5 53 L 293.5 339\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 355.5 53 L 355.5 339\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 418.5 53 L 418.5 339\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 482.5 53 L 482.5 339\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"286\" width=\"314\" x=\"168\" y=\"53\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 167.5 53 L 167.5 339\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"325\" y=\"378\">Total Prevalent Population<\/text><path class=\"highcharts-axis-line\" d=\"M 168 339 L 482 339\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"true\" class=\"highcharts-series highcharts-series-0 highcharts-area-series highcharts-color-0\" clip-path=\"url(#highcharts-8o90n3n-470-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(482,339) rotate(90) scale(-1,1) scale(1 1)\"><path class=\"highcharts-area\" d=\"M 238.33333333333 64.9666 L 143 184.9146 L 47.666666666663 194.05200000000002 L 47.666666666663 314 L 143 314 L 238.33333333333 314 Z\" data-z-index=\"0\" fill=\"rgb(124,181,236)\" fill-opacity=\"0.75\"><\/path><path class=\"highcharts-graph\" d=\"M 238.33333333333 64.9666 L 143 184.9146 L 47.666666666663 194.05200000000002\" data-z-index=\"1\" fill=\"none\" stroke=\"#7cb5ec\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\"2\"><\/path><\/g><g aria-hidden=\"false\" aria-label=\"\" class=\"highcharts-markers highcharts-series-0 highcharts-area-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(482,339) rotate(90) scale(-1,1) scale(1 1)\"><path aria-label=\"1. Fabry Disease Total Prevalent Population in the United States (2020), 7,931. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" d=\"M 238 69 A 4 4 0 1 1 238.00399999933333 68.99999800000016 Z\" fill=\"#7cb5ec\" opacity=\"1\" role=\"img\" style=\"outline: none;\" tabindex=\"-1\"><\/path><path aria-label=\"2. Fabry Disease Total Prevalent Population of Males in the US (2020), 4,111. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" d=\"M 143 189 A 4 4 0 1 1 143.00399999933333 188.99999800000018 Z\" fill=\"#7cb5ec\" opacity=\"1\" role=\"img\" style=\"outline: none;\" tabindex=\"-1\"><\/path><path aria-label=\"3. Fabry Disease Total Prevalent Population of Females in the US (2020), 3,820. Total Prevalent Population.\" class=\"highcharts-point highcharts-color-0\" d=\"M 47 198 A 4 4 0 1 1 47.00399999933334 197.99999800000018 Z\" fill=\"#7cb5ec\" opacity=\"1\" role=\"img\" style=\"outline: none;\" tabindex=\"-1\"><\/path><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"246\" y=\"24\">United States Epidemiological Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"246\" y=\"52\"><\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-area-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(168,53) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(228,24)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">7 931<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>7 931<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(108,119)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">4 111<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>4 111<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(99,214)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">3 820<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>3 820<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"153\" y=\"89\">Fabry Disease Total<tspan dy=\"14\" x=\"153\">\u200b<\/tspan>Prevalent Population in the<tspan dy=\"14\" x=\"153\">\u200b<\/tspan>United States (2020)<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"153\" y=\"185\">Fabry Disease Total<tspan dy=\"14\" x=\"153\">\u200b<\/tspan>Prevalent Population of<tspan dy=\"14\" x=\"153\">\u200b<\/tspan>Males in the US (2020)<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"153\" y=\"280\">Fabry Disease Total<tspan dy=\"14\" x=\"153\">\u200b<\/tspan>Prevalent Population of<tspan dy=\"14\" x=\"153\">\u200b<\/tspan>Females in the US (2020)<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"168\" y=\"358\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"230.8\" y=\"358\">2k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"293.6\" y=\"358\">4k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"356.4\" y=\"358\">6k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"419.2\" y=\"358\">8k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"471.162504196167\" y=\"358\">10k<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Delveinsight.com\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"482\" y=\"395\">Delveinsight.com<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-8o90n3n-471-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"United States Epidemiological Insights\"},\"subtitle\":{\"text\":\"\"},\"exporting\":{},\"chart\":{\"type\":\"area\",\"inverted\":true,\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Total Prevalent Population\\\"\\n\\\"Fabry Disease Total Prevalent Population in the United States (2020)\\\";7931\\n\\\"Fabry Disease Total Prevalent Population of Males in the US (2020)\\\";4111\\n\\\"Fabry Disease Total Prevalent Population of Females in the US (2020)\\\";3820\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"series\":[{\"name\":\"Total Prevalent Population\",\"turboThreshold\":0}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Delveinsight.com\",\"href\":\"https:\/\/www.delveinsight.com\"},\"yAxis\":[{\"title\":{\"text\":\"Total Prevalent Population\"}}]};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-95650063-6e53-479c-bc58-0632192dafbf\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fabry_Disease_Market_Insights\"><\/span><strong>Fabry Disease Market Insights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In recent years, factors such as increasing Fabry Disease prevalence, currently marketed therapies, along the promising emerging pipeline therapies with new mechanisms of action, the launch of these potential therapies are all anticipated to fuel the <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-market\">Fabry Disease market<\/a> in the coming years. According to DelveInsight, the Fabry Disease market size in the 7MM countries was estimated to be <strong>USD 1,195.3 million<\/strong> in the year 2020.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"504\" height=\"143\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28155244\/Fabry-Disease-Market-Size-in-the-7MM.png\" alt=\"Market Size of Fabry Disease\" class=\"wp-image-16771\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28155244\/Fabry-Disease-Market-Size-in-the-7MM.png 504w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28155244\/Fabry-Disease-Market-Size-in-the-7MM-300x85.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28155244\/Fabry-Disease-Market-Size-in-the-7MM-150x43.png 150w\" sizes=\"(max-width: 504px) 100vw, 504px\" \/><figcaption><strong>Market Size of Fabry Disease in 2020<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Many key pharmaceuticals that are proactively involved in producing <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-pipeline-insight\">Fabry Disease drugs<\/a> in the coming years include names such as <strong>Protalix Biotherapeutics, Sanofi Genzyme, Idorsia Pharmaceuticals, Avrobio, Sangamo Therapeutics, <\/strong><strong>Shire, Takeda, Amicus Therapeutics, Ozmosis Research Inc, CellGenTech, Inc, uniQure, Codexis, Canbridge, Eleva GmbH, MP6 therapeutics, Sigilon Therapeutics, <\/strong><strong>4D Molecular Therapeutics, and Freeline Therapeutics,<\/strong> whose key Fabry Disease treatment therapies are expected to be launched in the coming years and can also serve as a major booster for Fabry Disease treatment market.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28154630\/Pioneers-in-the-field-of-Fabry-Disease.png\" alt=\"Key Fabry Disease Market Players\" class=\"wp-image-16770\" width=\"533\" height=\"350\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28154630\/Pioneers-in-the-field-of-Fabry-Disease.png 533w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28154630\/Pioneers-in-the-field-of-Fabry-Disease-300x197.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28154630\/Pioneers-in-the-field-of-Fabry-Disease-150x98.png 150w\" sizes=\"(max-width: 533px) 100vw, 533px\" \/><figcaption><strong>Key Fabry Disease Market Players<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_Fabry_Disease_Treatment_Landscape\"><\/span><strong>Current Fabry Disease Treatment Landscape<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The market of Fabry Disease treatment is continuously evolving due to the presence of many existential therapies as well as several new therapies that are under research. Currently, there are only a few FDA-approved Fabry Disease treatment therapies, the first one is <strong>Sanofi Genzyme's<\/strong> enzyme replacement therapy (ERT) with <strong>Fabrazyme (agalsidase beta)<\/strong>. It has been the standard of care for Fabry Disease treatment since the year 2001. Fabrazyme can be considered as the only enzyme replacement Fabry Disease medication that has been FDA approved and has long-term efficacy and safety data. It received accelerated approval from the FDA in 2003. 18 years later, the FDA converted the enzyme replacement therapy treatment authorization to full, regular approval.<\/p>\n\n\n\n<p>Replagal (agalsidase alfa), developed by the <a href=\"https:\/\/www.delveinsight.com\/blog\/takeda-buys-shire-deal-worth\">Shire<\/a>, received European Commission approval as an Orphan Drug in August 2001 and in February 2007 in Japan with the marketing rights with Dainippon Sumitomo Pharma. It is currently approved as a Fabry Disease treatment therapy in almost38 countries but not in the US. Also, in addition to that is a Fabrazyme biosimilar <strong>agalsidase beta BS<\/strong>&nbsp; developed by <strong>JCR Pharmaceuticals <\/strong>and <strong>GlaxoSmithKline <\/strong>has been available in Japan since 2018. It has a pricing advantage over Fabrazyme and Replagal, the only Japan-originated therapeutic.<\/p>\n\n\n\n<p>Though enzyme replacement therapy (ERT) has several benefits, it also has serious limitations. These include an inconvenient dosing schedule every 2 weeks causing variation in enzyme levels, risk of infusion-related reactions and infections, and the possibility of developing antibodies against Fabry Disease treatment. To counteract these limitations, <strong>Amicus Therapeutics<\/strong> developed <a href=\"https:\/\/www.delveinsight.com\/blog\/regulatory\"><strong>Galafold<\/strong><\/a> which has been the most recent entrant in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-market\">Fabry Disease market<\/a> for the last 15 years.&nbsp;<\/p>\n\n\n\n<p>This Fabry Disease treatment therapy gained significant market share from the existing treatments as it alleviated the current unmet needs. Galafold is what researchers and scientists call a chaperone therapy, and is also the first of this class of medications. It represents better value for money and may also provide more clinical benefits to Fabry Disease patients. Galafold, however, is only eligible to patients with amenable mutations i.e. 35\u201350% of the overall Fabry Disease population. It is concluded that, for Fabry Disease, one-size-fits-all treatment is non-existent as of now.<\/p>\n\n\n\n<p>Although a number of novel and potential new therapies are under research, including new forms of ERT, substrate reduction therapy, mRNA therapy, and gene therapy to address the current challenges in the Fabry Disease treatment landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Emerging_Drugs_in_Fabry_Disease_Treatment_Pipeline\"><\/span><strong>Emerging Drugs in Fabry Disease Treatment Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In order to combat the current unmet needs of the Fabry Disease treatment market and to provide better treatment options, several major pharma players are working aggressively to develop new Fabry Disease therapies with a novel mechanism of action. Emerging therapies such as<strong> Pegunigalsidase alfa (Protalix Biotherapeutics), Venglustat (Sanofi Genzyme), Lucerastat (Idorsia Pharmaceuticals), AVR-RD-01 (Avrobio), ST-920 (Sangamo Therapeutics), 4D-310 (4D Molecular Therapeutics), <\/strong>and <strong>FLT190 (Freeline Therapeutics), <\/strong>and others are expected to enter the&nbsp; <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-market\">Fabry Disease treatment market<\/a> in the coming years.<\/p>\n\n\n\n<p>There are many <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-pipeline-insight\">Fabry Disease pipeline drugs<\/a> in different phases of development under clinical trials, which include -<\/p>\n\n\n\n<p><strong>PRX-102<\/strong> or <strong>Pegunigalsidase Alfa<\/strong> is an experimental Enzyme Replacement Therapy (ERT) that is currently under development by <strong>Protalix Biotherapeutics <\/strong>for Fabry Disease treatment. It is being developed using Protalix\u2019s plant-based ProCellEx platform, a plant cell culture expressed, and a chemically modified version of the recombinant \u03b1-GAL A protein. The company has completed three <strong>Phase III studies (BALANCE, BRIGHT, <\/strong>and <strong>BRIDGE).<\/strong> The final outcomes of the BALANCE study will be out in Q1 of 2022. In May 2020, the companies filed an application with the US Food and Drug Administration seeking the accelerated approval of PRX-102, given at a dose of 1 mg\/kg every other week, to treat adults with Fabry. After granting it priority review, the agency rejected the application in April 2021 due to issues with facility inspections and manufacturing processes, partially caused by travel restrictions during the COVID-19 pandemic. The decision was not associated with concerns related to the therapy\u2019s safety or effectiveness shown in clinical trials.&nbsp;<\/p>\n\n\n\n<p><strong>AVR-RD-01<\/strong> is an investigational lentiviral-based gene therapy developed by <strong>Avrobio <\/strong>for Fabry Disease treatment.&nbsp; It is a gene delivery system using a harmless virus that inserts the nonmutated form of the GLA gene containing information for making functional \u03b1- GAL A into the body. AVR-RD-01 is currently being tested in <strong>Phase I\/II.<\/strong> To support the use of AVR-RD-01 in a broad Fabry Disease population, the company expects to include female patients, eliminate antibody status exclusions and collect additional cardiovascular and CNS data in the FAB-GT trial. Avrobio is anticipated to plan a pivotal trial in order to support an FDA approval of AVR-RD-01 as first-line gene therapy for Fabry Disease treatment. If the FDA is under the agreement, this drug will be a fine competitor for Sanofi Genzyme\u2019s Fabrazyme.<\/p>\n\n\n\n<p><strong>Venglustat <\/strong>(also known as<strong> ibiglustat<\/strong>)<strong> <\/strong>is an orally administered small molecule, currently being investigated by Sanofi Genzyme as another potential <a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-pipeline-insight\">Fabry Disease drug<\/a>. Also, this drug is developed for the treatment of several other rare diseases as well. It is an inhibitor of an enzyme called glucosylceramide synthase (GCS) and modifies the enzyme substrates. GCS turns its substrate, ceramide, into glucosylceramide (GL-1) during lipid metabolism, a series of biochemical reactions that degrade and generate lipids. The molecule is in the <strong>Phase III<\/strong> stage of development for Fabry Disease treatment therapy. The company expects to file submission by the year 2025.<\/p>\n\n\n\n<p><strong>ST-920 <\/strong>is a gene therapy under investigation by <strong>Sangamo Therapeutics<\/strong>. It is a gene therapy that comprises an AAV vector carrying a GLA gene construct driven by a proprietary liver-specific promoter. It is designed to enable a patient\u2019s liver to produce a long-lasting and continuous supply of the \u03b1-Gal A enzyme. Preclinical studies of ST-920 showed a positive response, and based on the positive response, the FDA accepted the IND application of the gene therapy for Fabry Disease treatment, and the company initiated the <strong>Phase I\/II clinical study<\/strong> of the product.<\/p>\n\n\n\n<p><strong>FLT190 <\/strong>&nbsp;is a next-generation gene therapy that is under development by <strong>Freeline Therapeutics<\/strong>. It is a&nbsp; next-generation gene therapy that uses an adeno-associated virus (AAV8) as a vehicle to deliver a healthy copy of the GLA gene in the hopes that it will induce the production of normal \u03b1-GAL A. Preclinical data using a gene therapy platform for expression of the enzyme \u03b1-galactosidase A (GLA) has demonstrated safety and efficacy in various animal models. Based on these company initiated a <strong>Phase I\/II <\/strong>trial to evaluate FTL190 for Fabry Disease treatment. The interim data readouts are expected in 2022. It has also received orphan designation by the EMA.<\/p>\n\n\n\n<p><strong>4D-310 <\/strong>is a gene medicine engineered with a proprietary optimized Adeno-associated virus (AAV) capsid discovered by <strong>4D Molecular Therapeutics<\/strong> through its proprietary Therapeutic Vector Evolution platform. It holds promise for Fabry Disease treatment by using an AAV vector to deliver a functional copy of the GLA gene, resulting in \u03b1-GAL A production in target tissues. This Fabry Disease drug received Fast Track Designation from the FDA in the third quarter of 2020.<\/p>\n\n\n\n<p><strong>Idorsia Pharmaceuticals<\/strong> is developing a <strong>Lucerastat, <\/strong>a glucosylceramide synthase inhibitor, as a substrate reduction therapy for Fabry Disease treatment. It is an orally bioavailable small-molecule and low molecular weight iminosugar that inhibits glucosylceramide synthase and can provide substrate reduction. It offers a new treatment approach for people with Fabry Disease irrespective of their genetic mutation type.&nbsp;<\/p>\n\n\n\n<p><strong>Moss-aGal<\/strong> is an investigational Fabry Disease treatment therapy being developed by <strong>Greenovation Biotech GMBH,<\/strong> it is a recombinant form of human alpha-galactosidase produced in moss (physcomitrella patens) using Greenovation\u2019s BryoTechnology. Expression in moss creates a protein that is identical to the human protein with customized glycosylation patterns. The production is free of human pathogens and animal compounds. The production is free of human pathogens and animal compounds. The company has completed the <strong>Phase I trial<\/strong> of the product with positive results.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-1024x256.png\" alt=\"\" class=\"wp-image-16858\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/04\/01163504\/Fabry-Disease-Treatment-Market-Analysis.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Unmet_Needs_in_Fabry_Disease_Treatment_Domain\"><\/span><strong>Unmet Needs in Fabry Disease Treatment Domain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>There are several unmet needs still present in the Fabry Disease treatment landscape. It might include several factors such as many challenges faced during the diagnosis of Fabry Disease, the limitations which are found in the ongoing gene therapies used for treatment. Due to being a rare disease, the understanding of Fabry Disease is very poor, also, there is a need to develop more efficient clinical biomarkers for disease testing, with a novel Fabry Disease mechanism of action.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Way_Ahead\"><\/span><strong>Way Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Current Fabry Disease treatment market landscape is devoid of many therapies apart from those working on the basis of Enzyme Replacement Therapy. ERT definitely has changed&nbsp; the outcome of treatment in the Fabry Disease population, however, the enzyme must be delivered intravenously, which can be challenging as it requires repeated calculations. Although ERT is generally tolerated well, there is room for improvement, and to overcome these limitations, chaperone therapy is recently been introduced for Fabry Disease treatment as a new-age molecular therapeutic approach to protein misfolding diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_FAQs\"><\/span><strong>Frequently Asked Questions<\/strong> <strong>(FAQs)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1648461287561\"><strong class=\"schema-faq-question\"><strong>What is Fabry Disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Fabry Disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme called alpha galactosidase A (\u03b1-Gal A). Decreased activity of \u03b1-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout the body.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1648461343211\"><strong class=\"schema-faq-question\"><strong>Can Fabry Disease be cured?<\/strong><\/strong> <p class=\"schema-faq-answer\">Currently, there is no permanent cure for Fabry Disease. But, recent developments in the Fabry Disease treatment scenario are leading to a symptomatic cure, relieving the condition.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1648461366211\"><strong class=\"schema-faq-question\"><strong>Is Fabry Disease a terminal illness?<\/strong><\/strong> <p class=\"schema-faq-answer\">Fabry Disease is rare, inherited, and a serious genetic disorder. It is a lipid storage disorder that can cause long-term difficulties in the kidneys, heart, and nervous system. Fabry Disease can be understood as a terminal illness as well.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1648461389704\"><strong class=\"schema-faq-question\"><strong>Is Fabry Disease life-threatening?<\/strong><\/strong> <p class=\"schema-faq-answer\">Fabry Disease involves many potential life-threatening complications such as progressive kidney damage, heart attack, and stroke. It can be fatal.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fabry Disease Treatment Market<\/p>\n","protected":false},"author":14,"featured_media":16773,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[4295,19193,19195,19192,19194,19190,19191],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-16766","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-fabry-disease","tag-fabry-disease-drugs","tag-fabry-disease-epidemiology","tag-fabry-disease-pipeline","tag-fabry-disease-signs-and-symptoms","tag-fabry-disease-treatment","tag-fabry-disease-treatment-market","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Therapeutic Advancements in Fabry Disease Treatment | Rare Disease<\/title>\n<meta name=\"description\" content=\"Fabry Disease treatment market is continuously evolving due existence of new therapies as well as key pharmaceuticals involved.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic Advancements in Fabry Disease Treatment | Rare Disease\" \/>\n<meta property=\"og:description\" content=\"Fabry Disease treatment market is continuously evolving due existence of new therapies as well as key pharmaceuticals involved.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-28T12:17:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-16T06:23:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28160131\/Ultra-Rare-Fabry-Disease.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Therapeutic Advancements in Fabry Disease Treatment | Rare Disease","description":"Fabry Disease treatment market is continuously evolving due existence of new therapies as well as key pharmaceuticals involved.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Therapeutic Advancements in Fabry Disease Treatment | Rare Disease","og_description":"Fabry Disease treatment market is continuously evolving due existence of new therapies as well as key pharmaceuticals involved.","og_url":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-03-28T12:17:08+00:00","article_modified_time":"2022-12-16T06:23:13+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28160131\/Ultra-Rare-Fabry-Disease.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape","name":"Therapeutic Advancements in Fabry Disease Treatment | Rare Disease","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28160131\/Ultra-Rare-Fabry-Disease.png","datePublished":"2022-03-28T12:17:08+00:00","dateModified":"2022-12-16T06:23:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Fabry Disease treatment market is continuously evolving due existence of new therapies as well as key pharmaceuticals involved.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461287561"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461343211"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461366211"},{"@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461389704"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28160131\/Ultra-Rare-Fabry-Disease.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28160131\/Ultra-Rare-Fabry-Disease.png","width":772,"height":482,"caption":"Fabry Disease Treatment Landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461287561","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461287561","name":"What is Fabry Disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Fabry Disease is an inherited lysosomal storage disease caused by a nonfunctional or partially functional enzyme called alpha galactosidase A (\u03b1-Gal A). Decreased activity of \u03b1-Gal A in lysosomes results in the accumulation of enzyme substrates (Gb3 and lyso-Gb3) which cause cellular damage in tissues throughout the body.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461343211","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461343211","name":"Can Fabry Disease be cured?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Currently, there is no permanent cure for Fabry Disease. But, recent developments in the Fabry Disease treatment scenario are leading to a symptomatic cure, relieving the condition.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461366211","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461366211","name":"Is Fabry Disease a terminal illness?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Fabry Disease is rare, inherited, and a serious genetic disorder. It is a lipid storage disorder that can cause long-term difficulties in the kidneys, heart, and nervous system. Fabry Disease can be understood as a terminal illness as well.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461389704","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/fabry-disease-treatment-landscape#faq-question-1648461389704","name":"Is Fabry Disease life-threatening?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Fabry Disease involves many potential life-threatening complications such as progressive kidney damage, heart attack, and stroke. It can be fatal.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/03\/28160131\/Ultra-Rare-Fabry-Disease-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">fabry disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">fabry disease drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fabry Disease epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">fabry disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fabry Disease signs and symptoms<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">fabry disease treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">fabry disease treatment market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">fabry disease<\/span>","<span class=\"advgb-post-tax-term\">fabry disease drugs<\/span>","<span class=\"advgb-post-tax-term\">Fabry Disease epidemiology<\/span>","<span class=\"advgb-post-tax-term\">fabry disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Fabry Disease signs and symptoms<\/span>","<span class=\"advgb-post-tax-term\">fabry disease treatment<\/span>","<span class=\"advgb-post-tax-term\">fabry disease treatment market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Mar 28, 2022","modified":"Updated on Dec 16, 2022"},"absolute_dates_time":{"created":"Posted on Mar 28, 2022 5:47 pm","modified":"Updated on Dec 16, 2022 11:53 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=16766"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/16766\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/16773"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=16766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=16766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=16766"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=16766"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=16766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}